AZN vs IINN

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

IINN exhibits severe fundamental distress, characterized by a Piotroski F-Score of 4/9, which barely maintains a 'stable' rating despite catastrophic operational metrics. The company's operating margin of -4713.84% and a Price-to-Sales ratio of 64.07 indicate a massive disconnect between market valuation and actual revenue generation. With a 5-year price decline of 91% and a technical trend score of 0/100, the stock is in a persistent freefall. The absence of an Altman Z-Score and Graham Number further underscores the lack of positive earnings or stable equity to support a traditional valuation.